According to filings with the U.S. Securities and Exchange Commission, Ampel is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Operating Officer, Amrie Grammer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ampel
AMPEL BioSolutions was founded to bring personalized precision medicine to patients, especially those with autoimmune and inflammatory diseases. Autoimmune and inflammatory disease patients are not receiving the precise, personalized evaluation and treatment that they deserve. The immune system of autoimmune patients is complex, dynamic and not accurately assessed by current technologies. The AMPEL team brings their expertise in basic and translational research, clinical trial design, and bioinformatics together in a new way to develop scalable systems using AI and deep machine learning to improve patient outcomes. To give patients and their doctors the tools and information necessary to make decisions based on that individuals genomic profile what we term their Genomic Fingerprint.

To learn more about Ampel, visit http://ampelbiosolutions.com/

Contact:
Amrie Grammer, Chief Operating Officer
434-296-2675
https://www.linkedin.com/in/amrie-grammer-phd-1351551b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.